A new area of research is uncovering a surprising link between bone health, HIV, and the cardiovascular well-being of children and adolescents.
Imagine the body as a complex, interconnected network, where a signal sent from one department can have unexpected consequences in another. For children born to mothers with HIV—whether they acquired the virus themselves (perinatally HIV-infected, PHIV) or were exposed but uninfected (HEU)—their early start in life can cast a long shadow. Thanks to modern medicine, we can now prevent mother-to-child transmission, creating a growing population of resilient HEU children. But scientists are asking a crucial question: does the virus, or the powerful medications used to control it, leave a hidden biological signature that affects long-term health? Recent research points to an unlikely messenger from the bones that may be whispering secrets about the heart's future .
For decades, we thought of bones as simple scaffolding—a static frame that holds us up. We now know they are dynamic, living organs that produce powerful chemical messengers . Two of the most critical are:
Think of this as the bone's "phosphate manager." Produced by bone cells, its main job is to travel to the kidneys and instruct them to remove excess phosphate from the blood. Keeping phosphate in balance is crucial for energy production and cell function.
This acts as the "brake pedal" for bone growth. High levels of sclerostin tell the body to slow down bone formation. When levels are low, bone building can proceed at full speed.
The plot thickens when we discover that these bone markers don't just stay in the skeleton. They circulate throughout the body, and research shows they can directly influence the structure and function of the heart and blood vessels. This creates a fascinating "bone-heart axis."
Both perinatal HIV infection and exposure to antiretroviral therapy (ART) in the womb can disrupt the delicate balance of a child's developing body, potentially affecting both bone health and cardiovascular function.
To understand the connection between bone markers and heart health in HIV-affected children, researchers conducted a pivotal experiment as part of a large, long-term study .
Researchers enrolled a large cohort of children and adolescents, carefully categorizing them into PHIV, HEU, and HIV-unexposed uninfected (HUU) groups.
A single blood draw was taken from each participant. In the lab, scientists used sophisticated techniques to measure the precise levels of FGF-23 and sclerostin.
Each child underwent a detailed heart ultrasound (echocardiogram). This painless procedure allowed doctors to take precise measurements of the heart, including the thickness of its walls and its pumping efficiency.
Using statistical models, researchers analyzed the data to determine if higher levels of FGF-23 or sclerostin correlated with specific, measurable changes in the heart's structure.
| Tool / Reagent | Function |
|---|---|
| ELISA Kits | Measure specific proteins in blood samples |
| Ultrasound System | Detailed heart imaging |
| Antiretroviral Drugs | HIV treatment medications |
| Statistical Software | Data analysis and pattern identification |
The findings were striking and told a clear story about the relationship between bone markers and heart health.
Elevated levels of the bone hormone FGF-23 were strongly associated with potentially harmful changes in the heart's structure in both PHIV and HEU youth.
Specifically, higher FGF-23 was linked to a thickening of the heart's main pumping chamber (the left ventricle), a condition known as left ventricular hypertrophy (LVH).
| Characteristic | PHIV Children | HEU Children | HUU Children |
|---|---|---|---|
| Average Age | 12.5 years | 11.8 years | 12.1 years |
| On Antiretroviral Therapy | 100% | 0% | 0% |
| Exposed to ART in Womb | Yes | Yes | No |
| Average FGF-23 Level | Highest | Intermediate | Lowest |
| Heart Measurement | PHIV Children | HEU Children | HUU Children |
|---|---|---|---|
| Left Ventricle Mass Index (LVMi) | Highest | Intermediate | Lowest (Healthiest) |
| Ejection Fraction (% of blood pumped out) | Slightly Lower | Normal | Normal |
Left ventricular hypertrophy (LVH) is the heart's response to working too hard for too long. While it starts as an adaptation, over time it can lead to:
The association between a bone-derived hormone and this cardiac change in children highlights a previously overlooked pathway to heart disease .
This research marks a paradigm shift. It moves beyond viewing health problems in isolation and instead sees the body as an integrated system. The discovery that bone markers, particularly FGF-23, are linked to early heart changes in PHIV and HEU youth is a powerful warning sign—but also a beacon of hope.
By routinely monitoring FGF-23 levels in the blood, doctors might identify children at highest risk for future heart problems long before any symptoms appear.
This opens the door for tailored exercise programs, nutritional strategies, or medications to protect the hearts of these children as they grow into adulthood.
The legacy of perinatal HIV exposure is complex, but by listening to the secret language between bone and heart, we are learning how to write a healthier future for affected children.
Select a bone marker to learn more about its role in cardiovascular health:
Select a bone marker above to display information